- Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
-
Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH
- KMID: 2155291
- Clin Mol Hepatol.
- 2015 Mar;21(1):49-59.
- doi: 10.3350/cmh.2015.21.1.49
BACKGROUND/AIMS: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin... -
- CITED
-
- Close
- SHARE
-
- Close
- Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib
-
Kang D, Han Z, Oh GH, Joo Y, Choi HJ, Song JJ
- KMID: 2418924
- Yonsei Med J.
- 2017 Sep;58(5):899-909.
- doi: 10.3349/ymj.2017.58.5.899
PURPOSE: Sorafenib, a multikinase inhibitor, is the standard therapy for patients with advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the treatment, therefore, we tried to unravel the underlying mechanism... -
- CITED
-
- Close
- SHARE
-
- Close
